Abstract
In recent years, antiphospholipid antibodies (aPL) and their associated clinical features have been recognized increasingly in various pediatric autoimmune and non-autoimmune diseases. Pathogenic mechanisms involved in pediatric antiphospholipid syndrome (APS) appear to be the same as in adults. However, since pediatric patients do not have prothrombotic risk factors present in adults, there clearly are differences in the spectrum of clinical findings. The frequency of aPL-related thrombotic events is generally low in pediatric populations. On the other hand, various commonly acquired infections are likely to be responsible for higher percentage of non-pathogenic and transient aPL in childhood. Such points have to be considered in clinical judgment of elevated aPL in children. In this review we summarize the recent data on the prevalence and clinical significance of aPL in neonates, children and adolescents.
| Original language | English |
|---|---|
| Pages (from-to) | 4-10 |
| Number of pages | 7 |
| Journal | Lupus |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2002 |
Fingerprint
Keywords
- Antiphospholipid antibodies
- Antiphospholipid syndrome
- Childhood
ASJC Scopus subject areas
- Immunology
- Rheumatology
Cite this
Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. / Avčin, T.; Cimaz, R.; Meroni, Pier Luigi.
In: Lupus, Vol. 11, No. 1, 2002, p. 4-10.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations
AU - Avčin, T.
AU - Cimaz, R.
AU - Meroni, Pier Luigi
PY - 2002
Y1 - 2002
N2 - In recent years, antiphospholipid antibodies (aPL) and their associated clinical features have been recognized increasingly in various pediatric autoimmune and non-autoimmune diseases. Pathogenic mechanisms involved in pediatric antiphospholipid syndrome (APS) appear to be the same as in adults. However, since pediatric patients do not have prothrombotic risk factors present in adults, there clearly are differences in the spectrum of clinical findings. The frequency of aPL-related thrombotic events is generally low in pediatric populations. On the other hand, various commonly acquired infections are likely to be responsible for higher percentage of non-pathogenic and transient aPL in childhood. Such points have to be considered in clinical judgment of elevated aPL in children. In this review we summarize the recent data on the prevalence and clinical significance of aPL in neonates, children and adolescents.
AB - In recent years, antiphospholipid antibodies (aPL) and their associated clinical features have been recognized increasingly in various pediatric autoimmune and non-autoimmune diseases. Pathogenic mechanisms involved in pediatric antiphospholipid syndrome (APS) appear to be the same as in adults. However, since pediatric patients do not have prothrombotic risk factors present in adults, there clearly are differences in the spectrum of clinical findings. The frequency of aPL-related thrombotic events is generally low in pediatric populations. On the other hand, various commonly acquired infections are likely to be responsible for higher percentage of non-pathogenic and transient aPL in childhood. Such points have to be considered in clinical judgment of elevated aPL in children. In this review we summarize the recent data on the prevalence and clinical significance of aPL in neonates, children and adolescents.
KW - Antiphospholipid antibodies
KW - Antiphospholipid syndrome
KW - Childhood
UR - http://www.scopus.com/inward/record.url?scp=0036180864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036180864&partnerID=8YFLogxK
U2 - 10.1191/0961203302lu146rr
DO - 10.1191/0961203302lu146rr
M3 - Article
C2 - 11898917
AN - SCOPUS:0036180864
VL - 11
SP - 4
EP - 10
JO - Lupus
JF - Lupus
SN - 0961-2033
IS - 1
ER -